A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: A RTOG randomized study (#79-04)

International Journal of Radiation Oncology, Biology, Physics

Volumn 16, Issue 2, 1989, Pages 465-470

  Lee, Ding Jen ^a   Pajak, Thomas F ^c   Stetz, Joanne ^c   Order, Stanley E ^a   Weissberg, Joseph B ^b   Fischer, James J ^b  

^a Department of Therapeutic Radiology ^*  (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RADIATION THERAPY ONCOLOGY GROUP   (United States)

Author keywords

Head; Hypoxic cell sensitizer; Misonidazole; neck cancer

Indexed keywords

MISONIDAZOLE;

ADULT; AGED; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION; RADIOTHERAPY;

AGED; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN; MALE; MIDDLE AGE; MISONIDAZOLE; MULTICENTER STUDIES; PROSPECTIVE STUDIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RANDOM ALLOCATION; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024504773     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(89)90343-X     Document Type: Article

References (23)

1. Structure-activity relationships in the development of hypoxic cell radiosensitizers. 1. Sensitization efficiency
2. SR-2508 A Nitromidazole amide which should be superior to Misonidazole as a radiosensitizer for clinical use
3. Phase I trial of the hypoxic cell radiosensitizer SR-2508 the results of the five to six week drug schedule
4. The value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: an RTOG pilot study (#78-02)
5. Failure of Misonidazole-sensitized radiotherapy to impact upon outcome among stage III–IV squamous cancers of the head and neck
6. Causes of failure in irradiation of squamous cell carcinoma of the supraglottic larynx
7. Oxygen tension in human tumors: in vivo mapping using CT-guided probes
8. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
9. Radiotherapy and hyperbaric oxygen in head and neck cancer: final report of the first clinical trial
10. Radiotherapy and hyperbaric oxygen in head and neck cancer: interim report of the second clinical trial
11. Sensitizers and radiation dose fractionation: results and interpretations
12. Nonparametric estimation from encomplete observations
13. Short course high fractional dose irradiation in advanced and recurrent head and neck cancer
14. Radiotherapy with or without misonidazole for patients with stage IIIB or stage IVA squamous cell carcinoma of the uterine cervix preliminary report of a randomized trial
15. Evaluation of survival data and two new rank order statistics arising in its consideration
16. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study
17. Irradiation of advanced head and neck cancer with large daily fractions
18. Clinical trials of hypoxic cell sensitizers
19. Final report on the United States phase I clinical trial of the hypoxic cell radiosensitizer, misonidazole (RO-07-0582; NSC #2610307)
20. Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer
21. Large fraction irradiation with or without misonidazole in advanced non-oat cell carcinoma of the lung: a phase III randomized trial of the RTOG
22. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), and hypoxic cell sensitizer
23. Randomized trial of conventional versus high fractional dose radiation therapy in the treatment of advanced head and neck cancer